Technology Bundle ID: TAB-3261

Prefusion Coronavirus Spike Proteins and Their Use

Request More Info
Licensing Contact:
Primary Inventors: 
Barney Graham (NIAID)
Co-Inventors: 
Andrew Ward (Scripps Research Institute Immunology Lab), Christopher Cottrell (The Scripps Research Institute), Hadi Yassine (NIAID), Hannah Turner (The Scripps Research Institute), Jason McLellan (Geisel School of Medicine Dartmouth), Jesper Pallesen (The Scripps Research Institute), Kizzmekia Corbett (NIAID), Masaru Kanekiyo (NIAID), Michael Joyce (NIAID), Nianshuang Wang (Geisel School of Medicine at Dartmouth College), Robert Kirchdoerfer (The Scripps Research Institute)
Therapeutic Area: 
Infectious Disease
Institute or Center: 
NIAID

Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution. Past efforts to develop CoV vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit, or genetic approaches.

CoV spike (S) proteins mediate cellular attachment and membrane fusion and are therefore the target of protective antibodies. Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have developed a novel CoV S protein vaccine antigen. This technology employs protein engineering to stabilize S in its prefusion conformation, preventing structural rearrangement, and exposing antigenically preferable surfaces. The technology has been applied to several CoV spikes, including those from human-relevant viruses, such as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV, stabilized S proteins have been shown to elicit superior neutralizing antibody responses up to 10-fold higher in animal models and protect mice against lethal MERS-CoV infection. This technology is applicable for delivery via other platforms, such as mRNA.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Applications:
  • The stabilized prefusion coronavirus spike protein can be used as a vaccine antigen to elicit robust neutralizing antibody responses.
Advantages:
  • Improved immunogenicity compared to other coronavirus S vaccine formulations.
  • Increased protein expression, stability, and manufacturability compared to wild-type CoV S.

Patents

PCT Application PCT/US2017/058370
Filed on 2017-10-25
US Application 17/194,834
Filed on 2021-03-08
US Application 62/412,703
Filed on 2016-10-25
US Pat 10,960,070

Issued 2021-03-30

Updated

Apr 8, 2020

Data Source: 
tts